New classes of acute migraine therapies on the cusp of FDA approval look to fill in long-standing gaps in care.
Data from the phase 3b FOCUS trial demonstrates fremanezumab’s superior efficacy and tolerability in the prevention of migraine.
Epidemiology studies are useful to clinicians because they highlight diagnosis and prescribing patterns, common trends within a disease, and unmet needs.
At the recent American Headache Society meeting, researchers detailed the manifold risks of opioid use in patients with migraine.
Food insecurity and migraine, anxiety sensitivity and migraine severity, supraorbital stimulation to prevent chronic migraine—find summaries of these and other recent findings here.
Physicians should ask patients about their history of headaches and monitor for possible indicators of stroke, especially among older individuals who are already at increased risk.
Discussed in this video: Several novel modalities centered around migraine treatment and prevention.
Emgality (galcanezumab-gnlm) is the first FDA-approved drug that reduces the frequency of headache attacks.
A new tool to add to your armamentarium?
To kick off Migraine and Headache Awareness Month, the latest findings reported here may influence your approaches to diagnosis, treatment, and prevention and help you keep your patients informed.